近年来的研究显示,贝伐珠单抗联合化疗可延长晚期结肠癌患者的生存期[1]。笔者对2013年5月至2015年5月我院收治的晚期结肠癌患者分别采用贝伐珠单抗联合FOLFOX方案与单用FOLFOX方案进行治疗,观察比较两种方案的疗效和不良反应,现报告如下。1资料与方法1.1临床资料2013年5月至2015年5月在我科就诊的晚期结肠癌患者42例,男23例、女19例,年龄38~79岁、平均 In recent years, studies have shown that bevacizumab combined with chemotherapy can prolong the survival of patients with advanced colon cancer [1]. The author from May 2013 to May 2015 in our hospital for patients with advanced colon cancer were treated with bevacizumab combined with FOLFOX program and FOLFOX alone treatment was observed and compared the efficacy of the two programs and adverse reactions are reported as follows. 1 Materials and Methods 1.1 Clinical data May 2013 to May 2015 in our department for treatment of advanced colon cancer in 42 patients, 23 males and 19 females, aged 38 to 79 years, mean